ClinicalTrials.gg
RecruitingNCT04456491ASCONOUpdated Jul 21, 2023

The Clinical Value of the Nitric Oxide System Components in Asthma and COPD

An observational study in Asthma and COPD, sponsored by Ryazan State Medical University. Recruiting at 1 site in Russian Federation. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-07-21.

Sponsored by Ryazan State Medical University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Sep 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
240
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 140 studies in Asthma with a site in Russian Federation — 4 open to participants now, 4 under way, none of them phase 3. Asthma · Russian Federation.

Planned enrollment
9th of 10
240 · median 1,042
Started
2021
with 3 others
Observational
10 of 140
4 open now
Registered
129th of 140
by date

Among the 140 studies in Asthma with a site in Russian Federation, this one is the 9th largest by planned enrollment of the 10 observational ones that give a count, is one of 4 that started in 2021, is one of 10 observational ones, and was the 129th registered.

Asthma

4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.

Browse Asthma studies →

Open to participants now

4 of the 140 studies in Asthma with a site in Russian Federation are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Russian Federation have not opened yet or have stopped. Only those recruiting at a site in Russian Federation →

Who these studies take

Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 140 studies in Asthma with a site in Russian Federation, or all of them as a file.
02

Study summary

It is planned to conduct a study of nitric oxide metabolites (nitrates and nitrites), L-arginine, arginase-1, and asymmetric dimethylarginine in patients with bronchial asthma and chronic obstructive pulmonary disease, followed by observation to assess the prognosis of the disease.

Read the detailed description

Chronic obstructive pulmonary disease and bronchial asthma have a leading position among respiratory diseases. A significant contribution to the clinical picture and long-term prognosis is made by exacerbations of COPD, which makes it relevant to search for methods for their prediction and prevention. According to the global initiative on bronchial asthma (GINA), bronchial asthma is characterized by high heterogeneity and the existence of many phenotypes and endotypes, which makes it relevant to use personalized medicine methods in patient management and, in particularly, the search for new biomarkers of asthma. Currently, in clinical practice, some biomarkers of obstructive lung diseases are widely used. Among them there are the level of eosinophils in the blood and sputum, the level of immunoglobulin E and the exhaled fraction of nitric oxide (FeNO). Obstructive lung diseases are characterized by persistent inflammation in the airways, which is accompanied by the manifestation of elements of systemic inflammation and endothelial dysfunction, which is associated with an altered release of vasoactive mediators, one of them is nitric oxide (NO). NO is a powerful vasodilator that is synthesized from L-arginine using the enzyme NO synthase (NOS). The NO molecule has small lifetime from 3 to 30 s, that's why the search for biomarkers with a more stable lifetime is relevant. Some of them it's nitric oxide metabolites, such as nitrates (NO3-), nitrites (NO2-), S-nitrosothiols, 3-nitrotyrosine. Nitrates and nitrites, which are metabolites of nitric oxide, may be of interest as one of the promising biochemical markers reflecting NO metabolism in the human body. Earlier in our study, the relationship between the plasma level of nitric oxide metabolites and the severity of bronchial asthma was shown, which may be a prerequisite for further study of the components of the nitric oxide system as potential biomarkers of bronchial obstructive diseases.

A promising direction in the search for biomarkers related to the nitric oxide system is the study of L-arginine, which acts as a substrate in the reaction of NO formation. The bioavailability of L-arginine for NO synthases determines the activity of formation of nitric oxide in the respiratory tract, as evidenced by the effect of inhaled L-arginine on the level of exhaled fraction of nitric oxide. Earlier, in a US study, 26 patients with bronchial asthma showed a significant decrease in plasma L-arginine levels compared with healthy volunteers, and laboratory animal models showed that a decrease in L-arginine levels leads to airway hyperreactivity. Currently, a number of pilot clinical interventional studies have been carried out in which the administration of L-arginine improved the manifestations of bronchial asthma in some patients, but did not change the frequency of exacerbations in the total sample of patients. This indicates the possible existence of an endotype of bronchial asthma associated with impaired functioning of the nitric oxide system, and makes it promising to study the level of L-arginine in the blood as a potential biomarker of obstructive lung diseases.

In addition to studying nitric oxide metabolites, substances that affect the formation of NO should be considered as potential biomarkers of the disease. One such substance is arginase, under the influence of which L-arginine is converted into L-ornithine and urea. In humans, two isoenzymes of arginase, arginase 1 and arginase 2, have been identified, which differ in cellular location and tissue distribution. Both arginase enzymes are expressed in the airways and can be found in endothelial and epithelial cells, fibroblasts, macrophages, and smooth muscle cells of the respiratory tract. Further metabolism of L-ornithine leads to the formation of polyamines and L-proline, which are involved in cell proliferation and differentiation, as well as in the production of collagen. Scientists have shown that increased arginase activity in the airways contributes to airway obstruction and hyperreactivity by decreasing the availability substrate for NOS. As a result, the production of NO decreases and superoxides form, which react with NO to form peroxynitrite, thereby increasing airway contractility and inflammation. In addition, increased airway arginase activity leads to an increase in L-ornithine production, which potentially contributes to airway remodeling due to stimulation of cell proliferation and collagen formation.

The metabolism of L-arginine depends not only on arginase, but also on the methyltransferase enzyme, which methylates L-arginine residues, which undergo proteolysis with the formation of asymmetric and symmetric dimethylarginine (ADMA and SDMA). These amino acids inhibit NOS activity, since ADMA is a competitive inhibitor of the enzyme, while SDMA is a competitor to L-arginine transport. Serum ADMA and SDMA, as well as L-arginine concentrations increase with COPD and increase further with the development of exacerbation. It is important to note that the concentration of ADMA in blood serum is probably an independent risk factor for long-term mortality from all causes in obstructive lung diseases and is associated with increased airway resistance. In recent years, several studies have been conducted examining the association of ADMA with obstructive lung diseases. Earlier the association of ADMA with the development of obstructive lung diseases, airway resistance and indicators of the function of external respiration in patients with obstructive lung diseases was shown.

Thus, there are prerequisites for studying the components of the nitric oxide system, such as metabolites of nitric oxide, L-arginine, arginase, and asymmetric dimethylarginine, as a biomarker of obstructive lung diseases. Based on this, it is planned to study of nitric oxide metabolites (nitrates and nitrites), L-arginine, arginase-1, and asymmetric dimethylarginine in patients with bronchial asthma and chronic obstructive pulmonary disease, followed by observation to assess the prognosis of the disease.

The study is aimed at studying the clinical value of the nitric oxide synthesis modulators (L-arginine, arginase-1 and asymmetric dimethylarginine) in patients with bronchial asthma and chronic obstructive pulmonary disease, as well as assessing their effect on the prognosis and the course of diseases .

The study objectives is

  1. To assess the levels of modulators of the synthesis of nitric oxide (L-arginine, arginase-1 and asymmetric dimethylarginine) in the blood of patients with asthma and chronic obstructive pulmonary disease and their relationship with the clinical course of the disease.
  2. To evaluate the clinical value of the ratio of the levels of modulators of the synthesis of nitric oxide (L-arginine, arginase-1 and asymmetric dimethylarginine) and the level of metabolites of nitric oxide (nitrates and nitrites) in patients with bronchial asthma and chronic obstructive pulmonary disease.
  3. To assess the possibility of using the determination of the levels of modulators of nitric oxide synthesis to predict the course of obstructive lung diseases and prevent the development of exacerbations of bronchial asthma and chronic obstructive pulmonary disease.
  4. To assess the possibility of developing personalized treatment regimens for obstructive lung diseases, based on the assesment of the levels of modulators of the synthesis of nitric oxide (L-arginine, arginase-1 and asymmetric dimethylarginine) in the blood of patients with asthma and chronic obstructive pulmonary disease.

It is planned to conduct a prospective case-control study in the three study groups. To all patients will be performed: general clinical examination; Test of Adherence to Inhalers; clinical and biochemical analysis of the blood; spirometry; assesment of the level of nitric oxide metabolites in serum using the photocolorimetric method in Griss reaction; assesment of the level of L-arginine, arginase-1 and asymmetric dimethylarginine in serum by enzyme immunoassay using the laboratory kit Immundiagnostik (Germany). At the second phase of the study, lasting 2 years, the prognostic capabilities of assesment the levels of modulators of nitric oxide synthesis will be evaluated using a combined endpoint, included increase in level of basis therapy, exacerbation, hospitalisation and mors associated with Asthma and COPD.

03

Conditions studied

  • Asthma
  • COPD

Keywords

  • nitric oxide, arginine, arginase
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Asthma and COPD patients from Ryazan region which admitted in clinics of the Ryazan State Medical University

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • men and women aged between 18 and 70 years
  • a diagnosis of asthma or according to actual GINA and GOLD guidelines

Exclusion criteria

Exclusion Criteria:

  • decompensated pathology of the cardiovascular system;
  • history of liver dysfunction accompanied by an increase in , AST or total more than 3 times higher than the ;
  • history of severe renal impairment, accompanied by a decrease in below 60 ml/min (according to CKD-EPI);
  • abuse on psychoactive substances and / or alcohol.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
240 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Asthma

    Patients with Asthma

  • COPD

    Patients with COPD

  • Control group

    Healthy volunteers

06

What researchers measure

Primary outcomes

  1. Combined outcome - clinical worsening

    Combined outcome including increase in level of basis therapy, exacerbation, hospitalisation and mors associated with Asthma and COPD

    Time frame: 2 years

Secondary outcomes

  1. NO-metabolites

    Serum level of total nitric oxide metabolites (nitrites and nitrates summary)

    Time frame: At initial visit

  2. L-arginine

    Serum level of L-arginine

    Time frame: At initial visit

  3. Arginase-1

    Serum level of arginase-1

    Time frame: At initial visit

  4. ADMA

    Serum level of asymmetric dimethylarginine

    Time frame: At initial visit

07

Study locations

1 of 1 sites recruiting
  • Department of Therapy
    Ryazan', Ryazanskaya Obl. 390026, Russian Federation
    Recruiting
    • Anton Shakhanov, MD, PhD · Contact+79106359575
    • Zharkyniai Kanatbekova, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Jun 2025, 45 months after the start.

Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's planned 45 months is above that.

Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2020
First posted
Jul 2, 2020
StartActual
Sep 1, 2021
Primary completionEst.
Jun 30, 2025
CompletionEst.
Jun 30, 2025
Last update
Jul 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04456491
Lead sponsor
Ryazan State Medical University
Responsible party
Sponsor
First posted
Jul 2, 2020
Start date
Sep 1, 2021
Primary completion
Jun 30, 2025 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Jul 21, 2023

Study contacts

Anton Shakhanov, MD, Cand.Sci. (Med.)
Contact
shakhanovav@gmail.com
+7 910 635-95-75
Anton Shakhanov, MD, Cand.Sci. (Med.)
principal investigator · Ryazan State Medical University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion